Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated
transfusions given to patients with end-stage renal disease caused iron overload, and the …

Iron overload in renal failure patients: Changes since the introduction of erythropoietin
therapy. Iron overload was a common complication in patients with chronic renal failure …

In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …

Anaemia in chronic kidney disease (CKD) is managed primarily with erythropoiesis-
stimulating agents (ESAs) and iron therapy. Following concerns around ESA therapy …

The increasing prevalence of multiple comorbidities among anemic patients with chronic
kidney disease has made the use of serum ferritin and transferrin saturation more …

Progress in our understanding of iron-restricted erythropoiesis has been made possible by
important advances in defining the molecular mechanisms of iron homeostasis. The …

Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling,
and changes to practice guidelines and dialysis payment systems have provided strong …

Iron deficiency is common among patients with advanced kidney disease, particularly those
requiring hemodialysis. Intravenous iron is a convenient treatment to supplement iron and is …

Background Iron supplementation is crucial for the treatment of anemia of chronic kidney
disease (CKD). Although intravenous (IV) iron is preferred for patients with CKD receiving …

A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with
nondialysis-dependent CKD. Background Although iron deficiency frequently complicates …